Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Innovent Biologics Inc
(OP:
IVBXF
)
5.402
UNCHANGED
Last Price
Updated: 9:49 AM EDT, Aug 13, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
5.402
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
5.402
Today's Range
5.402 - 5.402
52wk Range
3.830 - 6.410
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal
July 27, 2024
Triastek will develop oral RNA therapeutics with Germany’s BioNTech based on its 3D printing technology. Triastek will receive a $10 million upfront payment and up to $1.2 billion in milestones, plus...
Via
Talk Markets
Week In Review: Samsung Biologics Signs $1 Billion Manufacturing Contract With US Biopharma
July 06, 2024
Samsung Biologics, a Korean CDMO, signed a $1.06 billion agreement to provide manufacturing services for an unnamed US pharma. The agreement is the largest that Samsung Bio has made since it was...
Via
Talk Markets
Performance
YTD
+0.04%
+0.04%
1 Month
+0.98%
+0.98%
3 Month
+8.70%
+8.70%
6 Month
+3.89%
+3.89%
1 Year
+23.17%
+23.17%
More News
Read More
Week In Review: Fosun Pharma Plans $690 Million Deal To Privatize Henlius, Its Biologics Subsidiary
June 30, 2024
Via
Talk Markets
Week In Review: Hengrui And Degron Announce $7.2 Billion In Drug Licensings
May 25, 2024
Via
Talk Markets
Sanofi, Innovent Biologics Collaborate On Cancer Treatments In China
August 04, 2022
Via
Benzinga
Week In Review: Sciwind, Sino Biological And Biocytogen Announce Deals
May 11, 2024
Via
Talk Markets
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
April 06, 2024
Via
Talk Markets
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities
March 23, 2024
Via
Talk Markets
Week In Review: EurekaBio Raises $40 Million To Support Lentiviral Vector Platform
March 09, 2024
Via
Talk Markets
Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal
March 02, 2024
Via
Talk Markets
Week In Review: AlphaGen And ArtBio Form China-US Radioligand Partnership
February 24, 2024
Via
Talk Markets
Week In Review: I-Mab Morphs Into US-Only Company; Sells China Assets For $80 Million
February 11, 2024
Via
Talk Markets
Week In Review: $1.7 Billion Collaboration Between Elpiscience And Astellas Is Final 2023 Deal
December 31, 2023
Via
Talk Markets
Week In Review: Tang Capital Offers $465 Million For LianBio Plus 80% Of Any Licenses/Divestments
December 02, 2023
Via
Talk Markets
Week In Review: Hengrui Out-Licenses Next-Gen PARP1 To Merck KGaA For $1.7 Billion
November 04, 2023
Via
Talk Markets
Week In Review: A Consortium Of China Drug Distributors Want To Acquire Poland's Neuca
August 26, 2023
Via
Talk Markets
Week In Review: Billion Dollar Deals - Moderna’s Shanghai Investment And F-Star’s Takeda Collaboration
July 08, 2023
Via
Talk Markets
Week In Review: CMBG Out-Licenses Two CAR-T Candidates To Janssen For $245 Million Upfront
July 01, 2023
Via
Talk Markets
Week In Review: Cullgen Signs $1.9 Billion Protein Degrader Deal With Astellas
June 17, 2023
Via
Talk Markets
Week In Review: Shanghai HighTide Therapeutics Files For Hong Kong IPO
June 10, 2023
Via
Talk Markets
Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC
May 13, 2023
Via
Talk Markets
Week In Review: China Biopharmas Announce Three Out-Licensing Deals Totaling $2 Billion
February 18, 2023
Via
Talk Markets
Week In Review: Structure Stages $161 Million US IPO For AI/Structure-Based Drug Development
February 04, 2023
Via
Talk Markets
Week In Review: Boston Scientific Pays $523 Million For Majority Stake In Beijing Acotec Scientific
December 17, 2022
Via
Talk Markets
Week In Review: Akeso Out-Licenses PD-1/VEGF To Summit In $5 Billion Pact
December 10, 2022
Via
Talk Markets
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.